Metabolism and cancer
Menendez’s Lab

DESCRIPTION

Unlocking the metabolic secrets of cancer: Our “Metabolism and Cancer” team studies how cellular metabolism drives cancer growth, drug resistance, and metastasis. We use cutting-edge laboratory experiments, computational tools and clinical trials to validate our discoveries in cancer patients.

MAIN RESEARCH LINES

CANCER METABOLISM
Metabolic inhibitors for cancer therapy
- Metabolic mechanisms of tumorigenesis & drug resistance
- Clinical development of anti-cancer metabolic drugs
Mitochondria, senescence, and cancer
- Mitochondria-based elimination of tumor-/metastasis-initiating cells
- Metabolic therapy-induced senescence (MTIS)
Metabolo-immunotherapy
- Tumor cell-intrinsic immunometabolism
- Metabolic/dietary interventions and immunotherapy
BIOCOMPOUNDS
- Natural biocompounds for cancer treatment
COMPUTATIONAL BIOLOGY & CHEMISTRY
- Mathematical modeling of cancer
- Computational design of anti-cancer metabolic drugs

Group members

Javier A. Menendez

Group leaders

Elisabet Cuyàs

Researchers

Established researcher (Miguel Servet)

Eila Serrano Hervás

Researchers

Postdoctoral researcher (INVESTIGO)

Sara Verdura

Researchers

Predoctoral researcher

Àngela Llop Hernández

Young investigators

Predoctoral researcher

Júlia López

Young investigators

Predoctoral researcher

Begoña Martín Castillo

Researchers

Established researcher (Unit of Clinical Research, ICO-Girona)

Eugeni López Bonet

Researchers

Established researcher (Hospital Trueta)

Publications

Laparoscopic Sleeve Gastrectomy in Patients with Severe Obesity Restores Adaptive Responses Leading to Nonalcoholic Steatohepatitis

27 de July de 2022/in Menendez's Lab/by miguel

Int J Mol Sci. 2022 Jul 15;23(14):7830. doi: 10.3390/ijms23147830. ABSTRACT The surgically induced remission of liver disease represents a model to investigate the signalling processes that trigger the development of nonalcoholic steatohepatitis with the aim of identifying novel therapeutic targets. We recruited patients with severe obesity with or without nonalcoholic steatohepatitis and obtained liver and […]

Metformin and breast cancer: an opportunity for pharmacogenetics

19 de July de 2022/in Menendez's Lab/by miguel

Aging (Albany NY). 2022 Jul 18;14(14):5612-5613. doi: 10.18632/aging.204180. Epub 2022 Jul 18. NO ABSTRACT PMID:35852878 | PMC:PMC9365564 | DOI:10.18632/aging.204180

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

13 de June de 2022/in Menendez's Lab/by miguel

Am J Cancer Res. 2022 May 15;12(5):2173-2188. eCollection 2022. ABSTRACT The HER3/4 ligand heregulin-β2 (HRG) is a secreted growth factor that transactivates the ligand-less receptor HER2 to promote aggressive phenotypes in breast cancer. HRG can also localize to the nucleus of breast cancer cells, but both the nuclear translocation mechanism and the physiological role of […]

Priority-based transformations of stimulus representation in visual working memory

2 de June de 2022/in Menendez's Lab/by miguel

PLoS Comput Biol. 2022 Jun 2;18(6):e1009062. doi: 10.1371/journal.pcbi.1009062. eCollection 2022 Jun. ABSTRACT How does the brain prioritize among the contents of working memory (WM) to appropriately guide behavior? Previous work, employing inverted encoding modeling (IEM) of electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) datasets, has shown that unprioritized memory items (UMI) are actively represented […]

Fatty acid synthase: a druggable driver of breast cancer brain metastasis

12 de May de 2022/in Menendez's Lab/by miguel

Expert Opin Ther Targets. 2022 May;26(5):427-444. doi: 10.1080/14728222.2022.2077189. Epub 2022 May 19. ABSTRACT INTRODUCTION: Brain metastasis (BrM) is a key contributor to morbidity and mortality in breast cancer patients, especially among high-risk epidermal growth factor receptor 2-positive (HER2+) and triple-negative/basal-like molecular subtypes. Optimal management of BrM is focused on characterizing a ‘BrM dependency map’ to […]

Collaborations

Ruth Lupu | Mayo Clinic, Rochester, USA

Pilar Blancafort | Harry Perkins Institute of Medical Research, Perth, Australia

Francesca Cutruzzolà | Sapienza University, Rome, Italy

Tomás Alarcón | ICREA-Centre de Recerca Matemàtica (CRM), Reus, Spain

Sílvia Osuna | ICREA-Institut de Química Computacional i Catàlisi (IQCC), Girona, Spain

Josep Sardanyés | Centre de Recerca Matemàtica (CRM), Barcelona, Spain

José Antonio Encinar | Universidad Miguel Hernández, Elche, Spain

Vicente Micol | Universidad Miguel Hernández, Elche, Spain

Antonio Segura-Carretero | Universidad de Granada, Granada, Spain

Jorge Joven | Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain

Carlos Peña Garay | Laboratorio Subterráneo de Canfranc (LSC), Spain

Metabolism and cancerMenendez’s Lab

DESCRIPTION

Javier A. Menendez

Group leaders

Elisabet Cuyàs

Researchers

Eila Serrano Hervás

Researchers

Sara Verdura

Researchers

Àngela Llop Hernández

Young investigators

Júlia López

Young investigators

Begoña Martín Castillo

Researchers

Eugeni López Bonet

Researchers

CONTACT US

Metabolism and cancer
Menendez’s Lab